Sucroferric oxyhydroxide for the treatment of hyperphosphatemia

References

• Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–921.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Sacks F, Pfeffer M, et al. Cholesterol, recurrent events trial I. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627−33.
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208−18.
   PubMed Web of Science ®Google Scholar
• Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20:388−96.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305:1119−27.
   PubMed Web of Science ®Google Scholar
• Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519−30.
   PubMed Web of Science ®Google Scholar
• Bellinghieri G, Santoro D, Savica V. Emerging drugs for hyperphosphatemia. Expert Opin Emerg Drugs. 2007;12:355−65.
   PubMed Web of Science ®Google Scholar
• Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis. 2012;60:90–101.
   PubMed Web of Science ®Google Scholar
• Cannata-Andia JB, Fernandez-Martin JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84:998−1008.
   PubMed Web of Science ®Google Scholar
• Barreto FC, de Oliveira RA, Oliveira RB, et al. Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opin Pharmacother. 2011;12:2627−40.
   PubMed Web of Science ®Google Scholar
• Bournerias F, Monnier N, Reveillaud RJ. Risk of orally administered aluminium hydroxide and results of withdrawal. Proc Eur Dial Transplant Assoc. 1983;20:207−12.
   PubMedGoogle Scholar
• Mudge DW, Johnson DW, Hawley CM, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol. 2011;12:20.
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7:578−89.
   PubMed Web of Science ®Google Scholar
• Mason MA, Shepler BM. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. Pharmacotherapy. 2010;30:741−8.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Del Vecchio L, Violo L, et al. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf. 2014;13:551−61.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang Y, Chen H, et al. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Ren Fail. 2014;36:1244−52.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268−77.
   PubMed Web of Science ®Google Scholar
• Sekercioglu N, Thabane L, Diaz Martinez JP, et al. Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis. PloS One. 2016;11:e0156891.
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Wilkie M. Use of magnesium as a drug in chronic kidney disease. Clin Kidney J. 2012;5(Suppl 1):i62−i70.
   PubMedGoogle Scholar
• de Francisco AL, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010;25:3707−17.
   PubMed Web of Science ®Google Scholar
• Renagel® (sevelamer hydrochloride) tablets for oral use. Highlights of Prescribing Information. 2007. [cited 2018 Jun 26]. Available from: http://products.sanofi.us/renvela/renvela.pdf.
   Google Scholar
• Pai AB, Shepler BM. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy. 2009;29:554−61.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant. 2009;24:278−85.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3:1125−30.
   PubMed Web of Science ®Google Scholar
• Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52:290−5.
   PubMed Web of Science ®Google Scholar
• Renagel® Tablet (sevelamer hydrochloride) 400 & 800mg. Prescribing information. Cambridge, MA, US: genzyme corporation; [ updated 2007; cited 2012]. Available from: http://www.renagel.com/docs/renagel_pi.pdf.
   Google Scholar
• Pierce D, Hossack S, Poole L, et al. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transplant. 2011;26:1615−21.
   PubMed Web of Science ®Google Scholar
• Takagi K, Masuda K, Yamazaki M, et al. Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins. Clin Nephrol. 2010;73:30−5.
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Wilson RJ, Garafola S, et al. Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton). 2016;21:987−94.
   PubMed Web of Science ®Google Scholar
• Haratake J, Yasunaga C, Ootani A, et al. Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol. 2015;39:767−71.
   PubMed Web of Science ®Google Scholar
• Makino M, Kawaguchi K, Shimojo H, et al. Extensive lanthanum deposition in the gastric mucosa: the first histopathological report. Pathol Int. 2015;65:33−7.
   PubMed Web of Science ®Google Scholar
• Ferric citrate (AURYXIA). Highlights of prescribing information, 2017 [cited 2018 Feb 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205874s013lbl.pdf
   Google Scholar
• Vifor Fresenius Medical Care Renal Pharma France. Velphoro 500 mg chewable tablets. Summary of product characteristics. 2017. [cited 2018 Mar 20]. Available from: https://www.medicines.org.uk/emc/medicine/29607#DOCREVISION
   Google Scholar
• Umanath K, Jalal DI, Greco BA, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015; Mar 3. Pii ASN.2014080842.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Akiba T, Fukagawa M, et al. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. J Ren Nutr. 2014;24:261−7.
   PubMed Web of Science ®Google Scholar
• Lenglet A, Liabeuf S, Guffroy P, et al. Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D. 2013;13:165−73.
   PubMedGoogle Scholar
• Block GA, Rosenbaum DP, Leonsson-Zachrisson M, et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28:1933−42.
   PubMed Web of Science ®Google Scholar
• Lanz M, Baldischweiler J, Kriwet B, et al. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm. 2014;40:1623−31.
   PubMed Web of Science ®Google Scholar
• Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol. 2016;29:329−40.
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Gaillard S, Rakov V, et al. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;81:251−8.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Funk F, Rakov V, et al. Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide. Curr Drug Metab. 2014;15:953−65.
   Google Scholar
• Phan O, Maillard M, Peregaux C, et al. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J Pharmacol Exp Ther. 2013;346:281−9.
   PubMed Web of Science ®Google Scholar
• Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010;74:4−11.
   PubMed Web of Science ®Google Scholar
• Chong E, Kalia V, Willsie S, et al. Drug−drug interactions between sucroferric oxhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. J Nephrol. 2014;27:659−66.
   PubMed Web of Science ®Google Scholar
• Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8:280−9.
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638−47.
   PubMed Web of Science ®Google Scholar
• Floege J, Covic A, Ketteler M, et al. Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30:1037−46.
   PubMed Web of Science ®Google Scholar
• Covic A, Floege J, Rastogi A, et al. Novel iron-based phosphate binder PA21 effectively reduces serum phosphorus in different subgroups of ESRD patients. Poster presented at: International Society of Nephrology-World Congress of Nephrology 2013, 31 May Jun 4, Hong Kong, Hong Kong.
   Google Scholar
• Floege J, Covic AC, Ketteler M, et al. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017;32:1918−26.
   PubMed Web of Science ®Google Scholar
• Covic AC, Floege J, Ketteler M, et al. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017;32:1330−8.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Covic AC, Floege J, et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. Am J Nephrol. 2016;44:104−12.
   PubMed Web of Science ®Google Scholar
• Sprague S, Covic A, Ketteler M, et al. Analysis of CKD-MBD markers in a Phase 3 study of PA21 and sevelamer in patients with hyperphosphatemia. Presented at: American society of nephrology kidney week 2013, 5–10 November, Atlanta GA, USA. J Am Soc Nephrol. 2013;24:755A.
   Google Scholar
• Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation. 2015;132:27−39.
   PubMed Web of Science ®Google Scholar
• Coyne DW, Ficociello LH, Parameswaran V, et al. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin Nephrol. 2017;88:59−67.
   PubMed Web of Science ®Google Scholar
• Coyne DW, Ficociello LH, Ofsthun NJ, et al. Effectiveness of sucroferric oxyhydroxide in lowering serum phosphorus in 4,925 chronic hemodialysis patients. Presentation at: American society of nephrology kidney week 2017, Oct 31−Nov 5, New Orleans, LA, USA. J Am Soc Nephrol. 2017;28:368
   Google Scholar
• Sprague SM, Parameswaran V, Ficociello LH, et al. Change in serum phosphorus and pill burden among hemodialysis patients switching from phosphate binder (PB) dual therapy to monotherapy with sucroferric oxyhydroxide (SO). Presented at: NKF 2017 spring clinical meetings April 18–22, 2017, Orlando, Florida, USA. Am J Kidney Dis. 2017;69:A1–A105.
   PubMed Web of Science ®Google Scholar
• Athienites N, Parameswaran V, Ficociello LH, et al. Change in serum phosphorus and serum albumin in hemodialysis patients with serum albumin ≤3.5 g/dl switching phosphate binder to sucroferric oxyhydroxide. Presented at: NKF 2017 spring clinical meetings April 18–22, 2017, Orlando, Florida, USA. Am J Kidney Dis. 2017;69:A25.
   Web of Science ®Google Scholar
• Kalantar-Zadeh K, Parameswaran V, Ficociello LH, et al. Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide. Am J Nephrol. 2018;47:153−61.
   PubMed Web of Science ®Google Scholar
• Vervloet MG, Boletis JN, de Francisco AM, et al. Evaluating the real-world safety and effectiveness of sucroferric oxyhydroxide in dialysis patients: an interim analysis of the VERIFIE Study. Presentation at: American Society of Nephrology Kidney Week 2017, Oct 31−Nov 5, New Orleans, LA, USA. J Am Soc Nephrol. 2017;28:632.
   PubMedGoogle Scholar
• Covic A, Ketteler M, Rastogi A, et al. Comparison of safety profiles of sucroferric oxyhydroxide (VELPHORO®; PA21) and sevelamer carbonate in a post hoc analysis of a phase 3 study. Poster presented at: European Renal Association–European Dialysis and Transplantation Association Annual Meeting 2013 Istanbul, Turkey, 18–21 May.
   Google Scholar
• Alu-Cap capsules. Summary of Product Characteristics. 2014. [cited 2018 Mar 20]. Available from: https://www.medicines.org.uk/emc/product/824.
   Google Scholar
• Phosex 1000mg tablets. Summary of product characteristics. 2012. [cited 2016 Jul 07]. Available from: http://www.medicines.org.uk/emc/medicine/14132.
   Google Scholar
• Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2009;24:3168−74.
   PubMed Web of Science ®Google Scholar
• Calcichew 500mg chewable tablets. Summary of Product Characteristics. 2017. [cited 2018 Mar 20]. Available from: http://www.medicines.org.uk/emc/medicine/28505.
   Google Scholar
• Floege J. Magnesium in CKD: more than a calcification inhibitor? J Nephrol. 2015;28:269–277.
   Google Scholar
• Phillips’ Milk of Magnesia. Summary of Product Characteristics. 2014. [cited 2018 Mar 20]. Available from: http://www.medicines.org.uk/emc/medicine/17293.
   Google Scholar
• Renvela (sevelamer carbonate) tablet, film coated for oral use/for oral suspension. Highlights of Prescribing Information. 2011. [cited 2016 Jul 07]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022318s003,022127s008lbl.pdf
   Google Scholar
• FOSRENOL (lanthanum carbonate) chewable tablets. Highlights of Prescribing Information. 2011. [cited 2016 Jul 07]. Available from: http://www.shirecontent.com/PI/PDFs/Fosrenol_USA_ENG.PDF.
   Google Scholar
• Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci. 2007;96:2818−27.
   PubMed Web of Science ®Google Scholar
• Covic A, Ketteler M, Rastogi A, et al. Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study. Poster presented at the 51st European Renal Association−European Dialysis and Transplant Association Annual Meeting 2014, 31 May 3 June Amsterdam, The Netherlands.
   Google Scholar
• Kissei Pharmaceutical Co. L. Press Release “New drug application approval for P-TOL®Chewable tablets” for the treatment of hyperphosphatemia in Japan. 28 September 2015. [cited 2018 Jun 26]. Available from: https://www.kissei.co.jp/e_contents/news/2015/20150928-651.html
   Google Scholar
• Wang S, Alfieri T, Ramakrishnan K, et al. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014;29:2092−9.
   PubMed Web of Science ®Google Scholar